![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CPT2 |
Gene summary for CPT2 |
![]() |
Gene information | Species | Human | Gene symbol | CPT2 | Gene ID | 1376 |
Gene name | carnitine palmitoyltransferase 2 | |
Gene Alias | CPT1 | |
Cytomap | 1p32.3 | |
Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | A0A140VK13 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1376 | CPT2 | LZE20T | Human | Esophagus | ESCC | 9.40e-06 | 1.63e-01 | 0.0662 |
1376 | CPT2 | LZE24T | Human | Esophagus | ESCC | 9.91e-05 | 1.82e-01 | 0.0596 |
1376 | CPT2 | LZE21T | Human | Esophagus | ESCC | 1.66e-02 | 1.58e-01 | 0.0655 |
1376 | CPT2 | P1T-E | Human | Esophagus | ESCC | 5.74e-05 | 2.17e-01 | 0.0875 |
1376 | CPT2 | P2T-E | Human | Esophagus | ESCC | 5.58e-22 | 3.27e-01 | 0.1177 |
1376 | CPT2 | P4T-E | Human | Esophagus | ESCC | 4.37e-11 | 1.79e-01 | 0.1323 |
1376 | CPT2 | P8T-E | Human | Esophagus | ESCC | 4.60e-12 | 1.31e-01 | 0.0889 |
1376 | CPT2 | P9T-E | Human | Esophagus | ESCC | 3.16e-05 | 9.80e-02 | 0.1131 |
1376 | CPT2 | P10T-E | Human | Esophagus | ESCC | 1.97e-12 | 2.16e-01 | 0.116 |
1376 | CPT2 | P11T-E | Human | Esophagus | ESCC | 1.58e-06 | 1.69e-01 | 0.1426 |
1376 | CPT2 | P12T-E | Human | Esophagus | ESCC | 5.15e-12 | 2.09e-01 | 0.1122 |
1376 | CPT2 | P15T-E | Human | Esophagus | ESCC | 9.72e-10 | 1.96e-01 | 0.1149 |
1376 | CPT2 | P16T-E | Human | Esophagus | ESCC | 2.04e-16 | 2.10e-01 | 0.1153 |
1376 | CPT2 | P17T-E | Human | Esophagus | ESCC | 1.99e-03 | 1.67e-01 | 0.1278 |
1376 | CPT2 | P19T-E | Human | Esophagus | ESCC | 1.28e-02 | 3.52e-01 | 0.1662 |
1376 | CPT2 | P20T-E | Human | Esophagus | ESCC | 5.18e-12 | 2.44e-01 | 0.1124 |
1376 | CPT2 | P21T-E | Human | Esophagus | ESCC | 1.38e-17 | 2.48e-01 | 0.1617 |
1376 | CPT2 | P22T-E | Human | Esophagus | ESCC | 2.55e-06 | 1.46e-01 | 0.1236 |
1376 | CPT2 | P23T-E | Human | Esophagus | ESCC | 1.69e-10 | 2.93e-01 | 0.108 |
1376 | CPT2 | P24T-E | Human | Esophagus | ESCC | 3.14e-07 | 1.32e-01 | 0.1287 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605411 | Liver | Cirrhotic | organic acid catabolic process | 104/4634 | 240/18723 | 1.91e-10 | 9.53e-09 | 104 |
GO:004639511 | Liver | Cirrhotic | carboxylic acid catabolic process | 102/4634 | 236/18723 | 3.41e-10 | 1.63e-08 | 102 |
GO:001939512 | Liver | Cirrhotic | fatty acid oxidation | 53/4634 | 103/18723 | 4.73e-09 | 1.88e-07 | 53 |
GO:003444011 | Liver | Cirrhotic | lipid oxidation | 53/4634 | 108/18723 | 3.85e-08 | 1.27e-06 | 53 |
GO:00017015 | Liver | Cirrhotic | in utero embryonic development | 134/4634 | 367/18723 | 2.78e-07 | 6.86e-06 | 134 |
GO:007232911 | Liver | Cirrhotic | monocarboxylic acid catabolic process | 56/4634 | 122/18723 | 2.87e-07 | 7.01e-06 | 56 |
GO:000906211 | Liver | Cirrhotic | fatty acid catabolic process | 48/4634 | 100/18723 | 3.87e-07 | 9.13e-06 | 48 |
GO:000663512 | Liver | Cirrhotic | fatty acid beta-oxidation | 38/4634 | 74/18723 | 7.41e-07 | 1.57e-05 | 38 |
GO:004424212 | Liver | Cirrhotic | cellular lipid catabolic process | 82/4634 | 214/18723 | 6.91e-06 | 1.08e-04 | 82 |
GO:001604212 | Liver | Cirrhotic | lipid catabolic process | 112/4634 | 320/18723 | 2.31e-05 | 3.03e-04 | 112 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:000657511 | Liver | Cirrhotic | cellular modified amino acid metabolic process | 70/4634 | 188/18723 | 9.04e-05 | 9.69e-04 | 70 |
GO:003025811 | Liver | Cirrhotic | lipid modification | 75/4634 | 212/18723 | 3.33e-04 | 2.87e-03 | 75 |
GO:19905425 | Liver | Cirrhotic | mitochondrial transmembrane transport | 41/4634 | 102/18723 | 4.08e-04 | 3.37e-03 | 41 |
GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
GO:000167611 | Liver | Cirrhotic | long-chain fatty acid metabolic process | 40/4634 | 112/18723 | 6.16e-03 | 3.06e-02 | 40 |
GO:000683912 | Liver | HCC | mitochondrial transport | 184/7958 | 254/18723 | 2.30e-22 | 3.83e-20 | 184 |
GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
GO:199054212 | Liver | HCC | mitochondrial transmembrane transport | 78/7958 | 102/18723 | 2.73e-12 | 1.26e-10 | 78 |
GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0541538 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa04714310 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0471414 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
hsa0541514 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0007121 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa0332021 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
hsa0471415 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
hsa0541515 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0007131 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa0332031 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
hsa0471422 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
hsa0541522 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa0007141 | Liver | HCC | Fatty acid degradation | 33/4020 | 43/8465 | 8.41e-05 | 4.27e-04 | 2.37e-04 | 33 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CPT2 | SNV | Missense_Mutation | c.711N>G | p.Asp237Glu | p.D237E | P23786 | protein_coding | deleterious(0.03) | possibly_damaging(0.631) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
CPT2 | SNV | Missense_Mutation | rs746186600 | c.1195N>T | p.Pro399Ser | p.P399S | P23786 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
CPT2 | SNV | Missense_Mutation | c.534G>C | p.Leu178Phe | p.L178F | P23786 | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CPT2 | SNV | Missense_Mutation | c.623A>G | p.Asn208Ser | p.N208S | P23786 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-D8-A1JH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | nolvadex | SD | |
CPT2 | SNV | Missense_Mutation | c.312A>T | p.Lys104Asn | p.K104N | P23786 | protein_coding | tolerated(0.13) | benign(0.154) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CPT2 | SNV | Missense_Mutation | rs750079911 | c.1508G>A | p.Arg503His | p.R503H | P23786 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-D8-A27N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol+adriamycin+cyclophosphamide+herceptin | SD |
CPT2 | SNV | Missense_Mutation | c.289G>A | p.Glu97Lys | p.E97K | P23786 | protein_coding | tolerated(0.71) | benign(0.012) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
CPT2 | insertion | In_Frame_Ins | novel | c.1556_1557insGATGGG | p.Glu519_Pro520insMetGly | p.E519_P520insMG | P23786 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
CPT2 | insertion | In_Frame_Ins | novel | c.1558_1559insCTA | p.Pro520_Ser521insThr | p.P520_S521insT | P23786 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
CPT2 | insertion | Nonsense_Mutation | novel | c.1095_1096insTCACTGATGACAAGGCCAGACACCTCCTGGTCCTAAGGAAAGGAA | p.Ser365_Thr366insSerLeuMetThrArgProAspThrSerTrpSerTerGlyLysGlu | p.S365_T366insSLMTRPDTSWS*GKE | P23786 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1376 | CPT2 | DRUGGABLE GENOME | PERHEXILINE | PERHEXILINE | ||
1376 | CPT2 | DRUGGABLE GENOME | PERHEXILINE | PERHEXILINE | ||
1376 | CPT2 | DRUGGABLE GENOME | PROPIONYL-L-CARNITINE |
Page: 1 |